(NYSE: NVO) Novo Nordisk (Ozempic)'s forecast annual revenue growth rate of 5.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Novo Nordisk (Ozempic)'s revenue in 2025 is $48,664,274,570.On average, 2 Wall Street analysts forecast NVO's revenue for 2025 to be $216,626,909,225,000, with the lowest NVO revenue forecast at $214,053,930,650,000, and the highest NVO revenue forecast at $219,199,887,800,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2026 to be $236,190,623,740,000, with the lowest NVO revenue forecast at $226,457,923,900,000, and the highest NVO revenue forecast at $254,819,380,650,000.
In 2027, NVO is forecast to generate $255,540,567,450,000 in revenue, with the lowest revenue forecast at $237,590,017,250,000 and the highest revenue forecast at $280,910,206,300,000.